BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, December 3, 2024
Breaking News: Healing a health divide (that’s long overdue)
See today's BioWorld Science
Home
» Deciphera Pharmaceuticals discovers new ULK and LRRK2 inhibitors
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Cancer
Deciphera Pharmaceuticals discovers new ULK and LRRK2 inhibitors
March 28, 2024
No Comments
Deciphera Pharmaceuticals LLC has described serine/threonine-protein kinase ULK1 and/or ULK2 and/or leucine-rich repeat kinase 2 (LRRK2; dardarin) inhibitors reported to be useful for the treatment of cancer.
BioWorld Science
Cancer
Patents
